PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2015 | 75 | Supl. |

Tytuł artykułu

Brain spingolipids in hyperglycemia

Warianty tytułu

Języki publikacji

EN

Abstrakty

EN
Ceramide (Cer) and sphingomyelin (SM) are members of sphingolipid (SL) family. Their concentrationsin the brain undergo substantial changes in many pathologies. They are also important players in diabetes-linked brain dysfunctions, in which increased content of ceramides can be toxic to neurons. The aim of the study was to evaluate selected parameters of sphingolipids and insulin pathways in prefrontal cortex (PC) and hippocampus (H) of rats with experimentally induced hyperglycemia. STZ-rat model of type 1 diabetes and high fat diet model of insulin resistance were used. Analyses of studied parameters were performed by GLC, IHC and Elisa. We found the augmented levels of ceramides in H and PC and only minor in striatum and cerebellum of rats with STZ-induced diabetes. Similar expressions of Cer were confirmed by IHC. Myriocin, an inhibitor of an enzyme of ceramide de novo synthesis pathway, reduced ceramide generation in hyperglycemic brains, particularly in PC, which was reflected in altered Cer synthase activities. In addition, we reported the fluctuations in sphingomyelin levels in investigated structures. The level of insulin did not change in H and PC of STZ-treated rats. An expression of insulin receptor and its phosphorylated form decreased in both structures, but was restored after myriocin administration. Similarly, Akt and phosphorylated Akt changed in these structures suggesting important role of de novo Cer synthesis in intracellular pathways of insulin. In the rat model of high fat diet, which leads to insulin resistance, the sphingolipid pattern (Cer and SM) was altered in H and PC as well. Metformin, the drug of choice in diabetes type 2, influenced the content of the above SLs in these structures, suggesting the additional central activity of antidiabetic treatment. We conclude that ceramide and SM may be important mediators of diabetes- accompanied brain dysfunction.

Słowa kluczowe

Wydawca

-

Rocznik

Tom

75

Numer

Opis fizyczny

p.S15

Twórcy

autor
  • Department of Experimental Pharmacology, Medical University of Bialystok, Bialystok, Poland
  • Department of Experimental Oncology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Bialystok, Poland
autor
  • Department of Experimental Pharmacology, Medical University of Bialystok, Bialystok, Poland
autor
  • Department of Experimental Pharmacology, Medical University of Bialystok, Bialystok, Poland
  • Department of Physiology, Medical University of Bialystok, Bialystok, Poland
autor
  • Department of Physiology, Medical University of Bialystok, Bialystok, Poland
autor
  • Department of Histology and Cytophysiology, Medical University of Bialystok, Bialystok, Poland
autor
  • Department of Biological Chemistry, Weizmann Institute of Science, Rehovot, Israel
  • Department of Biological Chemistry, Weizmann Institute of Science, Rehovot, Israel
autor
  • Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Science, Krakow, Poland
  • Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Science, Krakow, Poland

Bibliografia

Typ dokumentu

Bibliografia

Identyfikatory

Identyfikator YADDA

bwmeta1.element.agro-727d4805-573c-43c5-9b5b-e5b20e6d5edc
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.